Continuous positive airway pressure improves sleeping glucose levels in type 2 diabetics with obstructive sleep apnea
Research by a Michigan State University chemist could eventually lead to a quicker and easier way of developing protein-based drugs that are key to treating a number of diseases, including cancer, diabetes and hepatitis. Proteins used in drug manufacture and research often are made within genetically modified Escherichia coli , a one-cell bacteria. That protein
Full Post: New technique may provide quicker and easier way of developing protein-based drugs
A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine suggests that screening type 2 diabetes patients for obstructive sleep apnea (OSA) and treating those who have OSA with continuous positive airway pressure (CPAP) therapy could improve the management of their hyperglycemia and might favorably influence their long-term prognosis.
Results show that in a group of 20 type 2 diabetics who were mostly obese and were newly diagnosed with OSA, sleeping and nocturnal hyperglycemia were reduced and the sleeping interstitial glucose level was less variable during CPAP treatment. The average glucose level during sleep decreased by approximately 20 mg/dl after an average of 41 days of CPAP. The sleeping glucose also was more stable after treatment, with the median standard deviation decreasing from 20.0 to 13.0 and the mean difference between maximum and minimum values decreasing from 88 to 57.
According to Arthur Dawson, MD, senior consultant in the Division of Chest and Critical Care Medicine and co-director of research at Scripps Clinic Sleep Center in La Jolla, Calif., it is not surprising that many diabetics have sleep apnea since type 2 diabetes and OSA are both conditions that are becoming much more common because of the obesity epidemic.
Dawson said, “The low blood oxygen level and the arousals associated with an apneic event activate the sympathetic nervous system and cause the release of stress hormones, both of which tend to raise the blood glucose. If we could prevent these apneic events with CPAP then we might keep the glucose level lower and more stable through the night.”
According to the authors, population surveys, the Wisconsin Sleep Cohort and the Sleep Heart Health Study estimate the prevalence of type 2 diabetes in patients with OSA to be about 15 percent. OSA is associated with increased insulin resistance independent of obesity; 50 percent of patients with OSA have type 2 diabetes or impaired carbohydrate metabolism.
Twenty patients with type 2 diabetes who were on a stable diabetic regime were recruited at the time of their initial consultation with a sleep physician. All participants were newly diagnosed with moderate to severe OSA, and none had any previous experience with CPAP. Glucose level was monitored with a continuous glucose monitoring system (CGMS) over a period of 36 hours, which included a night in a sleep laboratory for evaluation by polysmnography. On the first night of the study, patients’ OSA was untreated. A second night of glucose monitoring and sleep recording was done after the participants had been on CPAP therapy for a duration of one-to-three months. No changes were made in participants’ diets or medication for diabetes throughout the study.
The authors report that previous studies have shown that variability of the glucose level increases the risk of eye complications and death in type 2 diabetics. Dawson said that the authors believe that recognizing and treating sleep apnea could improve the outlook for diabetics who also suffer from OSA. Researchers involved in this study theorized that by using the CGMS they were able to pick up short-term changes in the glucose level that would not be detected by traditional measurements.
A study in the Jan. 1 issue of the journal Sleep demonstrates that the frequent arousals from sleep that occur in heart failure patients with central sleep apnea (CSA) may reflect the presence of another underlying arousal disorder rather than being a defensive mechanism to terminate apneas. Principal investigator, Douglas Bradley, professor of medicine at
Full Post: Arousal frequency in heart failure found to be a unique sleep problem
Obstructive sleep apnea decreases blood flow to the brain, elevates blood pressure within the brain and eventually harms the brain’s ability to modulate these changes and prevent damage to itself, according to a new study published by The American Physiological Society. The findings may help explain why people with sleep apnea are more likely to
Full Post: Links between sleep apnea, stroke and death explained
Continuous positive airway pressure (CPAP) treatment seems to improve cognitive functioning in patients with Alzheimer’s disease who also suffer from obstructive sleep apnea, according to the results of a randomized clinical trial conducted at the University of California, San Diego. The study - led by Sonia Ancoli-Israel, Ph.D., professor of psychiatry at the UC San
Full Post: Alzheimer’s patients with sleep apnea benefit from CPAP treatment - improves cognitive abilities
Sleeping less than seven and a half hours per day may be associated with future risk of heart disease, according to a report in the November 10 issue of Archives of Internal Medicine. In addition, a combination of little sleep and overnight elevated blood pressure appears to be associated with an increased risk of the
Full Post: Lack of sleep tied to greater risk of heart disease
Diabetes and high levels of blood sugar may be linked to abnormalities in a person’s body clock and sleep patterns, according to a genome-wide association study published today in the journal Nature Genetics. The research suggests that diabetes and higher than normal blood sugar levels could partly be tackled by treating sleep problems, say
Full Post: Body clock and sleep patterns linked to diabetes and high blood sugar